Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy?

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.

Is IOVA a good stock to buy? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has experienced a decrease in activity from the world’s largest hedge funds in recent months. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was in 37 hedge funds’ portfolios at the end of March. The all time high for this statistic is 43. There were 41 hedge funds in our database with IOVA positions at the end of the fourth quarter. Our calculations also showed that IOVA isn’t among the 30 most popular stocks among hedge funds (click for Q1 rankings).

According to most investors, hedge funds are viewed as worthless, outdated financial tools of the past. While there are more than 8000 funds in operation at present, Our experts look at the top tier of this group, around 850 funds. These money managers have their hands on bulk of all hedge funds’ total capital, and by keeping an eye on their top investments, Insider Monkey has formulated a few investment strategies that have historically outstripped the broader indices. Insider Monkey’s flagship short hedge fund strategy defeated the S&P 500 short ETFs by around 20 percentage points per year since its inception in March 2017. Also, our monthly newsletter’s portfolio of long stock picks returned 206.8% since March 2017 (through May 2021) and beat the S&P 500 Index by more than 115 percentage points. You can download a sample issue of this newsletter on our website .

Cathie Wood of ARK Investment Management

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best battery stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Now we’re going to take a glance at the key hedge fund action encompassing Iovance Biotherapeutics, Inc. (NASDAQ:IOVA).

Do Hedge Funds Think IOVA Is A Good Stock To Buy Now?

Heading into the second quarter of 2021, a total of 37 of the hedge funds tracked by Insider Monkey were long this stock, a change of -10% from the fourth quarter of 2020. By comparison, 39 hedge funds held shares or bullish call options in IOVA a year ago. With the smart money’s capital changing hands, there exists a select group of notable hedge fund managers who were adding to their stakes significantly (or already accumulated large positions).

The largest stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was held by ARK Investment Management, which reported holding $624.5 million worth of stock at the end of December. It was followed by Perceptive Advisors with a $273.9 million position. Other investors bullish on the company included Avoro Capital Advisors (venBio Select Advisor), OrbiMed Advisors, and Farallon Capital. In terms of the portfolio weights assigned to each position Great Point Partners allocated the biggest weight to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), around 6.09% of its 13F portfolio. Avoro Capital Advisors (venBio Select Advisor) is also relatively very bullish on the stock, setting aside 4.37 percent of its 13F equity portfolio to IOVA.

Due to the fact that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has witnessed a decline in interest from the aggregate hedge fund industry, logic holds that there was a specific group of funds that elected to cut their positions entirely heading into Q2. At the top of the heap, Eli Casdin’s Casdin Capital said goodbye to the biggest investment of the “upper crust” of funds followed by Insider Monkey, comprising an estimated $25.5 million in stock, and Doron Breen and Mori Arkin’s Sphera Global Healthcare Fund was right behind this move, as the fund said goodbye to about $5.9 million worth. These transactions are interesting, as total hedge fund interest dropped by 4 funds heading into Q2.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) but similarly valued. We will take a look at Gates Industrial Corporation plc (NYSE:GTES), Bloom Energy Corporation (NYSE:BE), FuelCell Energy, Inc. (NASDAQ:FCEL), Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE:PAC), Turning Point Therapeutics, Inc. (NASDAQ:TPTX), PennyMac Financial Services Inc (NYSE:PFSI), and Silgan Holdings Inc. (NASDAQ:SLGN). This group of stocks’ market valuations resemble IOVA’s market valuation.

View table here if you experience formatting issues.

As you can see these stocks had an average of 19 hedge funds with bullish positions and the average amount invested in these stocks was $283 million. That figure was $1759 million in IOVA’s case. Turning Point Therapeutics, Inc. (NASDAQ:TPTX) is the most popular stock in this table. On the other hand Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE:PAC) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is more popular among hedge funds. Our overall hedge fund sentiment score for IOVA is 76.8. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 percentage points. These stocks gained 19.3% in 2021 through June 25th and still beat the market by 4.8 percentage points. Unfortunately IOVA wasn’t nearly as popular as these 5 stocks and hedge funds that were betting on IOVA were disappointed as the stock returned -14.6% since the end of the first quarter (through 6/25) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 5 most popular stocks among hedge funds as most of these stocks already outperformed the market since 2019.

Suggested Articles:

• How to Best Use Insider Monkey To Increase Your Returns
• 10 Best Gold Stocks to Buy in 2021
• Billionaire Mario Gabelli’s Top 10 Stock Picks

Disclosure: None. This article was originally published at Insider Monkey.